Skip to content
ClinCalc Pro
Menu
Macrolide antibiotic (anti-inflammatory / prophylactic)

Azithromycin (COPD Exacerbation Prophylaxis)

Brand names: Zithromax, Azithromycin (generic)

Azithromycin is a macrolide antibiotic used here as long-term prophylaxis to reduce the frequency of exacerbations in selected patients with COPD, typically those with frequent exacerbations despite optimised inhaled therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds the bacterial 50S ribosomal subunit to inhibit protein synthesis, and in this setting is thought to act partly through anti-inflammatory and immunomodulatory effects rather than antibacterial action alone.

Prescribing in practice

  • Most important: it prolongs the QT interval and risks serious arrhythmia, so obtain a baseline ECG and review concurrent QT-prolonging drugs before starting long-term use, per MHRA advice.
  • Exclude active non-tuberculous mycobacterial infection and consider sputum culture before initiating prophylaxis, as long-term macrolide monotherapy risks driving resistance.
  • Reserve for non-smokers or those who have stopped smoking, as the exacerbation benefit is reduced in current smokers; review the indication periodically.

Monitoring

Monitor with baseline and periodic ECG for QT prolongation, liver function, and hearing, and review continued need at intervals.

Counselling the patient

  • Report palpitations, fainting, or new hearing problems promptly.
  • Tell any prescriber you are taking long-term azithromycin before starting other medicines.

Evidence & guidelines

Long-term macrolide prophylaxis is supported by NICE and trials such as those underpinning reduced COPD exacerbation rates in selected frequent exacerbators.

Reference: NICE NG115 COPD; ALBERT Trial (Albert et al, NEJM 2011); BTS Bronchiectasis Guidelines 2019; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.